Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024)
Tango Therapeutics (TNGX) recorded quarterly Non Operating Investment Income of -$443000.0 in Q1 2024, down 151.1% quarter-over-quarter from $867000.0 in Q4 2023, and down 129.45% on a YoY basis from $1.5 million in Q2 2023.
Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024) Analysis & Trends
Tango Therapeutics' Non Operating Investment Income history runs 5 years deep, the most recent figure standing at -$443000.0 for Q1 2024.
- In Q1 2024, Non Operating Investment Income fell 129.45% year-over-year to -$443000.0; the TTM figure through Mar 2024 stood at $1.9 million (up 60.79% YoY), while the FY2025 annual figure was -$112000.0, down 174.67% from the prior year.
- Non Operating Investment Income was -$443000.0 for Q1 2024 at Tango Therapeutics, down from $867000.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $1.5 million in Q1 2023 to a low of -$2.6 million in Q1 2022.
- Historically, Non Operating Investment Income has averaged -$17866.7 across 5 years, with a median of -$9000.0 in 2020.
- The sharpest annual moves came in 2022 and 2023: Non Operating Investment Income slumped 17733.33% in 2022, then surged 264.24% in 2023.
- A 5-year view of Non Operating Investment Income shows it stood at -$9000.0 in 2020, then plunged by 8288.89% to -$755000.0 in 2021, then jumped by 252.45% to $1.2 million in 2022, then dropped by 24.67% to $867000.0 in 2023, then sank by 151.1% to -$443000.0 in 2024.
- The last three Non Operating Investment Income figures came in at -$443000.0 (Q1 2024), $867000.0 (Q4 2023), and $836000.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 230,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -443,000.00 |
| Mar 31, 2024 | -443,000.00 |
| Dec 31, 2023 | 867,000.00 |
| Dec 31, 2023 | 867,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Jun 30, 2023 | 684,000.00 |
| Jun 30, 2023 | 684,000.00 |
| Mar 31, 2023 | 1.50 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | -509,000.00 |
| Sep 30, 2022 | -509,000.00 |
| Jun 30, 2022 | -937,000.00 |
| Jun 30, 2022 | -937,000.00 |
| Mar 31, 2022 | -2.65 Mn |
| Mar 31, 2022 | -2.65 Mn |
| Dec 31, 2021 | -755,000.00 |
| Dec 31, 2021 | -755,000.00 |